


Consider entry into clinical trials for all eligible patients

Chemotherapy Algorithm for CML



Version: 7	Approved by Chair of Haematology Tumour Group: Dr A Laurie
Reason for Update: updated to include NICE criteria for use of dasatinib, nilotinib and ponatinib	
Prepared by: S Taylor	Date: 4.9.17